Further analysis indicated that most responders had HER2 amplification, with a subset also showing HER2 mutations, highlighting the insufficiency of exclusively relying on IHC to forecast the efficacy of T-DM1, differently from what is observed in breast and gastric cancer [50]. Here, ERBB2 is linked to gastric cancer.